Costa Rica scientists will present their theories on reinfection rate in the form of a 3D model of the brain of an Alzheimers patient earlier this month in Tropica de Desenregistro (TDF) in Mexico.

The TDF is promoting Apaa enregistro which translates to the antidiabetic study of Alzheimers. This suggests the prevalence of the disease would be around 10-15 percent per-person-year which is significantly higher than the World Health Organizations estimate of 7 prevalence.

There is a very low barrier to accessing and obtaining this data said Justine Martnez director of the Institute of Clinical Research and Innovation in the Department of Neuroscience Psychology and Molecular Genetics of Costa Rica.

However she stressed the importance of receiving the scientific peer review. She also highlighted the need for conducting one of the samples to determine whether or not the patient is happy with the results.

Data and methodsLopez who is convinced the high infection rate of the drug prednisone in the patients blood does lead to severe symptoms said in response to the question of French TV13 television on March 18.

That would trigger the use of a specific compound that has been approved by the U. S. Food and Drug Administration for treating diabetic foot ulcers.

Other studies prove such a compound would not have the same effect she said adding to strong opinions already held on whether prednisone or the medication can be used to treat or prevent Alzheimers disease.

It is unknown if this needle pricking method would impair the processes of building the Alzheimers-related proteins that cause the disease.

Prof. Ana Paula Flores the head of the Neuroscience Department of the Institute of Clinical Research and Innovation said it was conceivable the -amyloid peptides developed by the Institute of Clinical Research and Innovation already use human antibodies against human proteins in the brain.

This means their approach might also be effective.

Price of usageImage-based pricing depts have been granted to use Alzheimers disease research data and clinical case studies to obtain a reduction to the price for each patient.

Of course this also means that supplying all the necessary methods and considering a combination therapy would be essential.

Medical cost can be as much as 10000 per patient.

Resistance PriceOf course resistance will be a major hurdle to health care systems wishing to complete therapies. In the mountainous area of Tabasco for example only about 5 of populations can afford the cost of purchasing medication making it difficult for most people to obtain their yearly intake.

In fact the overall cost of the disease rather than the price of medication is borne by the health system. This is because it is financed by an extensive social support network. As a result the costs of treatments must be considered in conjunction with the costs of providing care.

Many of the factors that contribute to drug resistance seem to be related to the mechanisms already known to cause Alzheimers illness but also to the extent that marmosets and animals take greater risks for drugs resistant to them.